IPO News | Okoda Pharmaceuticals Hong Kong Stock IPO Prospectus Expires

The Zhitong Finance App learned that the Hong Kong Stock Prospectus submitted by Shanghai Orkeda Pharmaceutical Technology Co., Ltd. (abbreviation: Okeda Pharmaceutical) on January 26, 2026 expired on July 26, 2026. China Merchants Securities International and CCB International were co-sponsors.

According to the previous prospectus, Okoda is an R&D-driven specialty pharmaceutical company. Its core business covers R&D, production and commercialization of innovative drugs, focusing on major unmet clinical needs in the fields of central nervous system diseases, metabolic diseases, and rare diseases.

In terms of core competitiveness, the company has an innovative drug delivery platform developed independently, built an integrated internal system covering R&D, production, sales and marketing, and established a rich global product pipeline. The company uses the 505 (b) (2) registration path, focuses on specific treatment fields, and uses all in-house R&D, production and commercialization capabilities to achieve operational synergy.